Search Results

Hudson Therapeutics announced that Shaperon, an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding with Dong-A ST for the development of nanobody-based new drugs.

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has received a notification that the US Food and Drug Administration (“FDA”) has accepted its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to Stelara® (Ustekinumab), for substantive review.

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara ® (Ustekinumab).

Electra Therapeutics, Inc. today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.

Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.

NeuroBo Pharmaceuticals, Inc. (“NeuroBo”) (Nasdaq: NRBO), and Dong-A ST Co., Ltd. (“Dong-A”) (KOSE: A000640) today announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726.

Dong-A ST Co., Ltd., a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.

Dong-A ST (Min Young Kim, President and CEO) (KRX: 170900) announced that they signed an exclusive license-out and supply agreement on November 4, 2022, with Polifarma (Mehmet Asri, CEO) for NESP® biosimilar DA-3880.